Literature DB >> 21878541

SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.

Frans L Opdam, Jesse J Swen, Judith A M Wessels, Hans Gelderblom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21878541     DOI： 10.1158/1078-0432.CCR-11-1208

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  2 in total

Review 1.  Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.

Authors:  Filippo Merloni; Nicoletta Ranallo; Laura Scortichini; Riccardo Giampieri; Rossana Berardi
Journal:  Cancer Drug Resist       Date:  2019-09-19

2.  Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.

Authors:  Con Murphy; Stephen Byrne; Gul Ahmed; Andrew Kenny; James Gallagher; Harry Harvey; Eoin O'Farrell; Brian Bird
Journal:  Dose Response       Date:  2018-10-01       Impact factor: 2.658
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.